Tuberculosis vaccine H1IC - Valneva/AJ Vaccines

Drug Profile

Tuberculosis vaccine H1IC - Valneva/AJ Vaccines

Alternative Names: Adjuvanted TB subunit vaccine H1IC - Valneva/AJ Vaccines; Ag85B-ESAT-6-IC31; H1/IC31 vaccine; H1: IC31; H1IC

Latest Information Update: 18 Jan 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Intercell; Statens Serum Institut
  • Developer AJ Vaccines; Statens Serum Institut; Valneva
  • Class Adjuvants; Antituberculars; Recombinant fusion proteins; Subunit vaccines; Synthetic vaccines; Tuberculosis vaccines
  • Mechanism of Action Immunostimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Phase II Tuberculosis

Most Recent Events

  • 16 Jan 2017 Statens Serum Institut sold its vaccine production business to AJ Vaccines
  • 08 Jul 2016 Phase-II clinical trials in Tuberculosis (Prevention) in Tanzania, South Africa (IM) (Aeras pipeline, July 2016)
  • 10 Dec 2014 Phase II development is ongoing South Africa and Tanzania
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top